Core Insights - The company reported a revenue of 47.35 million yuan for the first half of 2025, representing a year-on-year decline of 17.15% [1] - The net profit attributable to shareholders was -14.82 million yuan, a decrease of 32.22% compared to the previous year [1] Financial Performance - Revenue for the first half of 2025: 47.35 million yuan, down 17.15% year-on-year [1] - Net profit attributable to shareholders: -14.82 million yuan, down 32.22% year-on-year [1] - Foreign revenue reached 9.44 million yuan, an increase of 7.60% year-on-year, driven by the recovery of import repair business and the export of gradient coils [1] Cost Management - Sales expenses decreased by 22.63% compared to the same period last year [1] - Management expenses reduced by 20.80% year-on-year [1] Research and Development - R&D expenses amounted to 16.50 million yuan, an increase of 34.79% year-on-year, accounting for 34.84% of total revenue [1] - Focus areas include MRI system integration technology, 7.0T and multi-core high-end RF detectors, and superconducting magnets [1] - Some R&D outcomes have already been applied to the company's products [1] Product Development - The company is expanding its medical imaging equipment product line and advancing new product registration and commercialization [1] - The digital X-ray machine (DR) has obtained medical device registration and is in the market promotion phase [1] - The CT project has completed prototype production and is in the new product registration review stage [1][2]

上海辰光医疗科技股份有限公司 第五届董事会第二十次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 8 月 26 日 证券代码：430300 证券简称：辰光医疗 公告编号：2025-095 2.会议召开地点：上海市青浦区华青路 1269 号 3.会议召开方式：现场会议 4.发出董事会会议通知的时间和方式：2025 年 8 月 16 日以书面、电话和微 信方式发出 5.会议主持人：董事长 王杰先生 6.会议列席人员：高级管理人员 7.召开情况合法、合规、合章程性说明： 会议的召集、召开和表决程序符合有关法律、行政法规、规范性文件和《公 司章程》的规定。 （二）会议出席情况 会议应出席董事 9 人，出席和授权出席董事 9 人。 二、议案审议情况 （一）审议通过《2025 年半年度报告及其摘要》 1.议案内容： 该 议 案 具 体 内 容 详 见 公 司 在 北 京 证 券 交 易 所 官 方 信 息 披 露 平 台 （w ...

证券代码：430300 证券简称：辰光医疗 公告编号：2025-099 上海辰光医疗科技股份有限公司 关于开立募集资金现金管理专用结算账户的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 近日，公司为更好的开展现金管理，在中国建设银行股份有限公司上海长三 角一体化示范区支行开立了募集资金现金管理专用结算账户，用于使用暂时闲置 募集资金购买理财产品，账户具体信息如下： | | 开户机构 | 账户名称 | 账号 | | --- | --- | --- | --- | | 序号 | | | | | | 中国建设银行股份有限 | 上海辰光医疗科技股 | | | --- | --- | --- | --- | | 1 | 公司上海长三角一体化 | | 31050283360000000159 | | | | 份有限公司 | | | | 示范区支行 | | | 公司开立的现金管理专用结算账户不会存放非募集资金或用作其他用途，在 理财产品到期且无下一步理财产品购买计划时，存放于上述账户的理财本金及累 计的理财收 ...

证券代码：430300 证券简称：辰光医疗 公告编号：2025-098 上海辰光医疗科技股份有限公司 2025 年半年度募集资金存放、管理与实际使用情况 的专项报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、募集资金基本情况 (一) 募集资金总额、净额及资金到账时间 上海辰光医疗科技股份有限公司（以下简称"公司"、"辰光医疗"）经中国 证券监督管理委员会《关于核准上海辰光医疗科技股份有限公司向不特定合格投 资者公开发行股票的批复》(证监许可[2022]2882 号)核准，向不特定合格投资 者公开发行人民币普通股 1,500.00 万股，发行价为每股人民币 6.00 元，共计募 集资金总额为人民币9,000.00万元，扣除券商承销佣金及保荐费900.00万元后， 主承销商国泰海通证券股份有限公司于 2022 年 11 月 30 日汇入公司募集资金监 管账户中国建设银行股份有限公司上海长三角一体化示范区支行账户(账号为： 31050183360009998888)人民币 3,600.00 万元，汇 ...

上海辰光医疗科技股份有限公司 关于公司取得发明专利证书的公告 证券代码：430300 证券简称：辰光医疗 公告编号：2025-100 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、基本情况 上海辰光医疗科技股份有限公司（以下简称"公司"、"辰光医疗"）近日取 得国家知识产权局颁发 2 项《发明专利证书》，具体情况如下： 1、发明名称：一种动态环境下的超导磁体线圈结构 专利号：ZL 2021 1 0854614.6 专利申请日：2021 年 07 月 28 日 专利权人：上海辰光医疗科技股份有限公司 地址：201707 上海市青浦区华青路 1269 号 授权公告号：CN 113470922 B 该专利属于超导磁体技术领域，本发明提供一种动态环境下的超导磁体线圈 结构，用于降低超导线圈的失超风险。 2、发明名称：一种磁共振成像系统用发射线圈的结构 专利申请日：2021 年 06 月 29 日 专利权人：上海辰光医疗科技股份有限公司 地址：201707 上海市青浦区华青路 1269 号 授权公告号：CN ...

Group 1 - The core stock price of Chen Guang Medical as of July 29, 2025, is 17.96 yuan, reflecting a decrease of 1.97% from the previous trading day [1] - The trading volume on that day was 34,842 hands, with a total transaction amount of 63 million yuan [1] - Chen Guang Medical operates in the medical device industry, focusing on the research, development, production, and sales of medical superconducting magnetic resonance imaging systems and related equipment [1] Group 2 - The latest announcement indicates that the first extraordinary general meeting of shareholders in 2025 approved several resolutions, including the cancellation of the supervisory board and the revision of related systems, as well as the abolition of certain regulations and the formulation of revised internal management systems [1] - These resolutions aim to further improve the company's governance structure [1] Group 3 - The capital flow analysis shows a significant net outflow of main funds for Chen Guang Medical on that day, with large single orders showing a trend of outflow while the flow of small and medium-sized orders remained relatively stable [1]

（文章来源：证券日报） 证券日报网讯 7月29日晚间，辰光医疗发布公告称，公司2025年第一次临时股东会审议通过了《关于取 消监事会并修订的议案》《关于废止的议案》《关于制定及修订公司部分内部管理制度的议案》。 ...

证券代码：430300 证券简称：辰光医疗 公告编号：2025-093 上海辰光医疗科技股份有限公司 2025 年第一次临时股东会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 7 月 25 日 下午 14:30 2.会议召开地点：上海市青浦区华青路 1269 号 3.会议召开方式：本次会议采用现场投票和网络投票相结合方式召开 6.召开情况合法合规的说明： 本次股东会会议召开符合有关法律、行政法规、部门规章、规范性文件和《公 司章程》的规定。会议召开不需要相关部门批准或履行必要程序。 （二）会议出席情况 出席和授权出席本次股东会的股东共 5 人，持有表决权的股份总数 25,753,959 股，占公司有表决权股份总数的 29.9998%。 其中通过网络投票参与本次股东会的股东共 0 人，持有表决权的股份总数 0 股，占公司有表决权股份总数的 0.0000%。 （三）公司董事、监事、高级管理人员出席或列席股东会情况 1.公 ...

关于上海辰光医疗科技股份有限公司 2025 年第一次临时股东会 之 法律意见书 上海市海华永泰律师事务所 上海总部:上海市浦东新区陆家嘴环路 1366 号富士康大厦 12 层 电话:8621-58773177 传真:8621-58773268 二零二五年七月 : 上海市海华永泰律师事务所 关于上海辰光医疗科技股份有限公司 2025年第一次临时股东会 之 法律意见书 致:上海辰光医疗科技股份有限公司 上海市海华永泰律师事务所（以下简称"本所"）接受上海辰光医疗科技股 份有限公司(以下简称"公司")的委托,指派本所王依来律师(以下简称"经 办律师")出席了公司 2025年第一次临时股东会会议(以下简称"本次股东会"), 根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民共和 国证券法》(以下简称"《证券法》")、中国证券监督管理委员会发布的《上市 公司股东会规则》(以下简称"《股东会规则》")、《上海辰光医疗科技股份有 限公司章程》(以下简称"《公司章程》")和《上海辰光医疗科技股份有限公 司股东会议事规则》(以下简称"《股东会议事规则》")等规定,对本次股东 会的相关事宜依法见证,并出具本法律意 ...

Core Viewpoint - The financial performance of Chen Guang Medical has deteriorated significantly since its IPO, with continuous revenue decline and negative cash flow raising concerns about its operational viability [2][3][4]. Financial Performance - Revenue decreased from 188 million yuan in 2022 to 119 million yuan in 2024, while net profit shifted from a profit of 23.48 million yuan to a loss of 60.90 million yuan [2]. - Operating cash flow has been negative for three consecutive years, with a total outflow exceeding 66 million yuan [2]. Strategic Challenges - The company attributes its performance decline to three main pressures: external market conditions, a contraction in supply chain from key client Philips, and increased competition in the MRI market [3][4]. - The MRI market has become increasingly competitive, with over 15 companies, including international brands, entering the space, making it difficult for new entrants like Chen Guang Medical to establish a foothold [4]. Asset Quality Concerns - The company's accounts receivable stood at 69.38 million yuan in 2024, with a 16.31% decrease from the beginning of the period, while bad debt provisions increased by 34.67% [4][6]. - Inventory value rose by 11.07% to 119 million yuan, with a significant increase in the provision for inventory impairment by 657.43% [6]. R&D and Sales Expenses - Despite a 28.16% drop in revenue, R&D expenses surged by 46.83% to 29.44 million yuan, and sales expenses increased by 56.39% to 29.63 million yuan [5]. - The rise in R&D costs is primarily due to investments in high-end superconducting magnets, while sales expenses were driven by an expansion of the sales team [5]. Debt and Liquidity Issues - By the end of 2024, the company's cash reserves fell by 40.15% to 52.83 million yuan, while short-term loans increased by 34.28% to 131 million yuan, leading to a debt ratio of 48.34% [6][7]. - The company has indicated that it has a remaining credit line of 151 million yuan, but ongoing negative cash flow raises concerns about its ability to meet debt obligations [7]. Future Strategies - The company plans to enhance its core business by continuing to promote superconducting MRI sales, participating in medical device expos, and expanding into new product lines such as DR and CT [8][9]. - Efforts to improve cash flow include strengthening accounts receivable collection, reducing excess positions, and controlling inventory levels [7][8].